Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul;61(5-6):395-8.
doi: 10.1007/s00228-005-0950-5. Epub 2005 Jun 11.

Thiopurine S-methyltransferase as a target for drug interactions

Affiliations

Thiopurine S-methyltransferase as a target for drug interactions

Hua-Wen Xin et al. Eur J Clin Pharmacol. 2005 Jul.

Abstract

Objective: The present study was undertaken to investigate the possible effects of various agents on thiopurine methyltransferase (TPMT) activity in red blood cells (RBCs) from patients with chronic inflammatory bowel disease (IBD).

Methods: In three groups of patients with very high, normal and intermediate TPMT activity (each n=6), the inhibitory potential of furosemide, piretanide, azathioprine (AZA) and testosterone was assessed by ex vivo measurements of TPMT activity in RBCs. From individual concentration-response curves, IC50 values have been determined.

Results: Independent of the basal TPMT activity, lowest IC50 values were calculated for furosemide (15-19 microM), followed by testosterone (30-72 microM), piretanide (300-313 microM) and AZA (430-532 microM). Compared with reported plasma concentration achieved during treatment, only furosemide would have the potential to inhibit TPMT also in vivo, whereas the IC50 values of the other agents are far above the corresponding plasma levels.

Conclusions: Our ex vivo study revealed that only furosemide has the potential to inhibit TPMT activity in patients with IBD. This possibility should be taken into consideration if the diuretic and AZA or 6-mercaptopurine are coadministered. However, the extrapolation to the clinical setting remains open.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ther Drug Monit. 1997 Jun;19(3):318-26 - PubMed
    1. Clin Gastroenterol Hepatol. 2004 Sep;2(9):725-30 - PubMed
    1. Eur J Clin Pharmacol. 1998 May;54(3):265-71 - PubMed
    1. Clin Pharmacokinet. 1992 Apr;22(4):308-18 - PubMed
    1. N Engl J Med. 2002 Aug 8;347(6):417-29 - PubMed

Publication types

MeSH terms

LinkOut - more resources